BiotechTube

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Mar 1, 2005 → Feb 1, 2006

NCT ID
NCT00104247

About sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT00104247. Target conditions include Phenylketonurias.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00104247Phase 3Completed

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
SapropterinBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
49
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
Pegvaliase-PqpzBioMarin PharmaceuticalPre-clinical
20
PalynziqBioMarin PharmaceuticalPre-clinical
20
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74

Other Products from BioMarin Pharmaceutical

NaglazymeApproved
82
saproterin dihydrochlorideApproved
82
Pegvaliase + MethotrexateApproved
82
Kuvan®Approved
82
KuvanApproved
82